Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Orchestra BioMed Holdings, Inc. - Ordinary Shares (NQ:OBIO)

4.020 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	50
Open	4.020
Bid (Size)	3.910 (100)
Ask (Size)	4.800 (500)
Prev. Close	4.020
Today's Range	4.020 - 4.020
52wk Range	2.200 - 6.160
Shares Outstanding	38,194,442
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics

January 12, 2026

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting

December 08, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

Performance

YTD	-6.7%	-6.7%
1 Month	-5.2%	-5.2%
3 Month	+1.8%	+1.8%
6 Month	+50.0%	+50.0%
1 Year	-28.0%	-28.0%

More News

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 26, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

November 11, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

November 10, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

Orchestra BioMed to Host Business Update Call on November 12, 2025

November 03, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements

October 28, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial

October 27, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 10, 2025

Via Benzinga

Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit

October 09, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout

September 04, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 26, 2025

Via Benzinga

Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology

August 26, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

This Applied Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

August 20, 2025

Via Benzinga

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction

August 14, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

August 12, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 08, 2025

Via Benzinga

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

August 08, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

August 05, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

August 01, 2025

Via Benzinga

Orchestra BioMed Announces Pricing of $40 Million Public Offering

August 01, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 31, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

July 31, 2025

Via Chartmill

Orchestra BioMed Announces Proposed Public Offering

July 31, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

July 31, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Orchestra BioMed Holdings, Inc. - Ordinary Shares publicly traded?

Yes, Orchestra BioMed Holdings, Inc. - Ordinary Shares is publicly traded.

What exchange does Orchestra BioMed Holdings, Inc. - Ordinary Shares trade on?

Orchestra BioMed Holdings, Inc. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Orchestra BioMed Holdings, Inc. - Ordinary Shares?

The ticker symbol for Orchestra BioMed Holdings, Inc. - Ordinary Shares is OBIO on the Nasdaq Stock Market

What is the current price of Orchestra BioMed Holdings, Inc. - Ordinary Shares?

The current price of Orchestra BioMed Holdings, Inc. - Ordinary Shares is 4.020

When was Orchestra BioMed Holdings, Inc. - Ordinary Shares last traded?

The last trade of Orchestra BioMed Holdings, Inc. - Ordinary Shares was at 02/02/26 04:00 PM ET

What is the market capitalization of Orchestra BioMed Holdings, Inc. - Ordinary Shares?

The market capitalization of Orchestra BioMed Holdings, Inc. - Ordinary Shares is 153.54M

How many shares of Orchestra BioMed Holdings, Inc. - Ordinary Shares are outstanding?

Orchestra BioMed Holdings, Inc. - Ordinary Shares has 154M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.